Annual Meetings

Ever Changing Landscape of the Prescription Drug Crisis

FDA's Perspective to Changing Landscape

Falsified Medication Use in the General Population

Getting Specific: New tools for understanding overdose and drug supply

SAMHSA's Emerging Perspective on Psychedelics

Addressing Adverse Events

Comparable But Not Identical - The Unique Surveillance Needs of Psychedelics

Insights from NSIHT Pilot - National Survey Investigating Hallucinogenic Trends

Surveillance of Psychoactive Drugs: Opioids, Psychedelics, and Cannabinoids

Application of Systems Science in Opioid Misuse to Psychedelic Drugs

Cannabis: Lessons Learned from the Public Experience in Colorado

Policy Suggestions to Support the Safe Uses of Psychedelics

Assessing Polysubstance Use of Licit (Gabapentin, Xylazine) and Illicit Substances

Defining Polysubstance Use in a National Population-based Survey

Satisfying the Craving for Novel Psychoactive Post-Market Surveillance

Evolving Safety of Psychoactive Drugs

Heterogeneous Patterns of Stimulant Initiation: A Study of Typologies

Does Over-the-Counter Mean Under the Radar?

Abuse Trends In Over-The-Counter Medications

Am I Dreaming? The Misuse and Abuse of Psychedelics - A Mosaic Perspective of Psychedelics Landscape

Psychedelics in the Real World: Using Real World Evidence to Prepare for Approval

Fake Drugs, Real Risk: Answered and Unanswered Questions about Counterfeit Drugs: Targeted Literature Review

Postmarketing Surveillance: What’s the Next Move?

Meeting the Challenges of COVID-19 in Postmarketing Surveillance

Defining Populations of Interest for Post-Marketing Studies

Prescribing and Over-The-Counter Drugs; A Vast Range of Misusing Opportunities

Understanding Stimulant Use in the General Population: Prevalence and Patterns of Non-Medical Use

It’s not Easy Being Buprenorphine: Identifying Unique Substance Use Patterns Associated with Buprenorphine

FDA’s Holistic Approach to Addressing Polysubstance Use and the Drug Overdose Crisis

A New Frontier: Prescription Drug Abuse Beyond Opioids

Drug overdose statistics from the National Vital Statistics System

One Drug? Two Drugs? Polydrug Mortality Is More Common Than We Think

Key Priorities for FDA’s Controlled Substances Program

Pharmacoepidemiologic Research on Drugs of Abuse

How Low Can You Go: Solving the Challenge of Low Volume Endorsements in the General Population

International Pre-Symposium:
Canada and the Global Mosaic: How Does Prescription Drug Abuse Compare?

International Pre-Symposium:
Canadian Approach to Prescription Opioid Risk Management

International Pre-Symposium:
Codeine in Canada – Don’t Forget Weak Opioids…

International Pre-Symposium:
Emerging Changes in Opioid Diversion in Canada and the United States

International Pre-Symposium:
Who’s Winning? Opioid Abuse Patterns in the United States and Canada

Annual Meeting:
Welcome and RADARS® System 2018 Data Updates

Annual Meeting:
Project Lazarus: Local Solutions to National Opioid Crisis; What They Need to Know

Annual Meeting:
The Epidemiology of Prescription Opioid Abuse: A Regulatory Perspective

Annual Meeting:
Mortality Involving Prescription Drugs

Annual Meeting:
Lessons from Opana® ER: Policy, Behavior, and Reality

Annual Meeting:
The Route to Utilization of Trend-in-Trend

Annual Meeting:
Comment: Using Trend-in-Trend to Evaluate Drug Abuse

Annual Meeting:
Drug Diversion in Healthcare Facilities: Our Nation’s Little Secret

International Pre-Symposium:
The Global Mosaic: Is Prescription Drug Misuse Really Different Among Countries?

International Pre-Symposium:
The Growing Nexus Between NARCOS and Counterfeit Medicines

International Pre-Symposium:
Acute Harms of Prescription Drug Misuse: What Can We Learn from the European Drug Emergencies Network (Euro-DEN) Plus Project

International Pre-Symposium
Understanding the Evolution of the Opioid Epidemic in Canada, and the Risks of Poly-Substance Use

Annual Meeting:
Welcome and RADARS System 2017 Data Updates

Annual Meeting:
Effectiveness of ADFs in the Real World

Annual Meeting:
Understanding Changes in the US ‘Heroin’ Market: Notes from the Field

Annual Meeting:
The Illicit Injection of Prescription Opioids in Scott County, Indiana: Risks and Rewards

Annual Meeting:
FDA’s Current Approach to the Postmarket Evaluation of Opioid Analgesic Products with Properties Intended to Deter Abuse

Annual Meeting:
Thinking Outside the Opioid Box: Non-Opioid Pharmaceutical Abuse

International Pre-Symposium: Global Insights in Prescription Drug Misuse

International Pre-Symposium: Opioid Surveillance and Policy Evaluation: A Canadian Perspective

International Pre-Symposium: Comparative Assessments of the Prescription Drug Abuse Climate in Europe and the United States

International Pre-Symposium: Cross-Border Trafficking of Prescription Oxycodone Products Manufactured in Canada

Annual Meeting Welcome and RADARS System 2016 Data Updates

Annual Meeting: Behind the Opioid Epidemic – Fentanyl, Immediate Release Opioids, and Mortality

Annual Meeting: Darknet Drug Markets

Annual Meeting: Abuse Deterrent Formulations of Opioids

Annual Meeting: Evaluating the Impact of Abuse Deterrent Formulations

Annual Meeting: Abuse Deterrent (Tamper Resistant) Formulations State of the Evidence 2017

Annual Meeting: RAPID Analysis of Routes of Administration

International Pre-Symposium:
Prescription Drug Misuse – A Global Crisis?

International Pre-Symposium:
Non-Prescription Fentanyl: Canadian Fentanyl Trends Moving to the US

International Pre-Symposium:
Misuse of Medications in the UK and Related Advisory Council on Misuse of Drugs (ACMD) Activities

International Pre-Symposium:
Trends of Prescription Drug Misuse in the UK and Singapore

Annual Meeting:
Welcome and RADARS® System 2015 Data Updates

Annual Meeting:
Prescription Opioid and Heroin Abuse in the United States

Annual Meeting:
Setting the Stage: Are Abuse Deterrent Formulations Ready for Prime Time?

Annual Meeting:
NSDUH Trends in Nonmedical Use of Prescription Opioids

Annual Meeting:
Abuse Deterrent Opioids: Lessons for the “Downward Spiral”

Annual Meeting:
The Political Factors Affecting the Abuse Deterrent Formulations

Annual Meeting:
Drug Diversion Investigators

Annual Meeting:
Street Prices

Annual Meeting:
Patients Entering Substance Abuse Treatment